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Objective: Tuberculosis (TB) is one of the leading fatal infectious diseases and remains a major health problem worldwide. Moreover, adverse 
effects of TB treatment can escalate treatment default. This study aimed to evaluate the correlation between adverse reactions to anti-TB drugs and 
treatment default.  
Methods: We performed a cross-sectional study using medical record data of a total 172 adult patients with pulmonary TB who were treated with first-
line anti-TB drugs at Dr. Cipto Mangunkusumo National General Hospital in Jakarta, Indonesia during 2014 and who experienced adverse reactions.  
Results: Of the total, 127 patients (73.8%) had minor adverse reactions and 45 patients (26.2%) experienced major adverse reactions. Predominant 
adverse reactions included gastrointestinal disorders (34%) and drug-induced hepatitis (60%). There was a significant correlation between adverse 
reactions to anti-TB drugs and treatment default cases (odds ratio (OR), 9.33; 95% confidence interval (CI), 4.20–20.72; p<0.001). The results of 
multivariate analysis showed that TB treatment outcome is affected by adverse drug reactions (OR, 10.91; 95% CI, 4.62–25.75; p<0.001), drug use in 
treating concomitant diseases (OR, 3.03; 95% CI, 1.30–7.05; p=0.010), and type of anti-TB drug used (OR, 2.41; 95% CI, 0.99–5.83; p=0.045).  
Conclusion: Based on these results, we showed that adverse reactions to anti-TB drugs can affect TB treatment outcome and can serve as a risk 
factor to treatment default.  
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INTRODUCTION 
Tuberculosis (TB) is one of the leading fatal infectious diseases and 
remains a major health problem worldwide. In 2013, the World 
Health Organization (WHO) estimated that there were more than 9 
million incident TB cases, 64% of which were new sputum smear-
positive cases, and that about 3 million TB cases remain 
undiagnosed with 1.5 million TB-related deaths worldwide. In 2015, 
Indonesia become the country with the second highest incidence of 
TB globally, with a total 0.7–1.4 million cases per year [1]. About, 
75% of TB cases occur in economically productive age groups (15–
50 y), leading to an average loss of working time of 3–4 mo and 
causing annual income losses of up to 30%. Based on Ministry of 
Health data, Indonesia’s success rate for TB treatment reached 85% 
percent among new smear-positive TB cases in 2013, slightly below 
the national target of 88% [2]. The factors contributing to TB 
treatment outcome include patient compliance, patient knowledge 
and behavior related to TB, and health services. Moreover, patient 
adverse reactions to TB treatment might escalate treatment default 
[3]. Based on these facts, additional evidence regarding the influence 
of adverse reactions to anti-TB drugs may reveal an important 
determinant in the prevention of treatment default. Hence, further 
investigation is needed regarding whether adverse reactions to anti-
TB drugs indeed represent an independent etiologic factor that may 
contribute to the outcome of TB treatment. The objective of this 
study was to determine whether there was a correlation of TB 
treatment default cases with drug side effects and other aspects of 
TB treatment. 
MATERIALS AND METHODS 
Study design, setting, and participants  
We performed a cross-sectional study using secondary data of adult 
patients with pulmonary TB who had experienced adverse anti-TB 
drug reactions. All data were collected from medical records of Dr. 
Cipto Mangunkusumo National General Hospital during 2014. In this 
study, we included the data of a total 172 patients, based on the 
following inclusion criteria: adult patient with pulmonary TB who 
received first-line anti-TB drug treatment and experienced adverse 
reactions. Adverse reactions were classified into major 
(hypersensitivity, drug-induced hepatitis, and hearing loss or 
equilibrium disorders) and minor (red-colored urine, 
gastrointestinal tract disorders, visual impairment, paresthesia, skin 
disorders, headache, muscle and joint pain, and flu-like syndrome) 
adverse effects, based on Indonesian guidelines for TB diagnosis and 
management by the Ministry of Health Indonesia (2013) [4].  
Variable definitions  
Adverse reactions to first-line anti-TB drugs were defined as 
unexpected effects after receiving anti-TB drugs (rifampicin, 
isoniazid, pyrazinamide, ethambutol, and streptomycin). In this 
study, adverse reactions were classified into major and minor 
adverse effects, with signs and symptoms as described above. 
Outcomes of TB treatment in this study were divided into two 
categories: treatment default and completed treatment. Treatment 
default is defined as interruption of treatment for more than 2 
consecutive months. Completed treatment is defined as treatment 
completion for the determined duration of treatment (6 mo for first-
line treatment). 
Other potential variables that could affect treatment outcome were 
also included in this study and extracted for analysis, as follows: 
socioeconomic status, comorbid diseases, and drug use for comorbid 
diseases. The definition of socioeconomic status is a measure of class 
standing influenced by social class, educational level, income, and 
occupation. In this study, we also categorized patient data according 
to age group (15–54 y,>54 y), sex (female/male), and occupation 
(unemployed, government worker, self-employed, private sector 
employee, farmer, and other).  
Data analysis  
Quantitative data were analyzed using IBM SPSS 20 software (IBM 
Corp., Armonk, NY, USA). The chi-square test was used for bivariate 
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analysis and variables with p value<0.20 were included in 
multivariate analysis using logistic regression. 
Ethics 
Ethical approval to conduct the study was obtained from the Faculty 
of Medicine, Universitas Indonesia Research and Ethics Committee. 
Permission to conduct this study was also given by the Center for 
Clinical Epidemiology and Evidence-Based Medicine, Dr. Cipto 
Mangunkusumo National General Hospital. 
RESULTS 
Participant characteristics 
From a total 172 patients included in this study, 127 patients 
(73.8%) experienced minor adverse reactions to anti-TB drugs, and 
45 patients (26.2%) had major adverse reactions (table 1). The 
predominant major adverse reactions were drug-induced hepatitis 
(60%), hypersensitivity (24%), and hearing loss or equilibrium 
disorders (16%) (fig. 1). Minor adverse reactions included 
gastrointestinal tract disorders (34%), paresthesia (16%), red-
colored urine (13%), skin disorders (9%), muscle and joint pain 
(9%), visual impairment (6%), headache (5%), and others (8%) (fig. 
2). In this study, 70 patients (40.7%) had comorbidities requiring 
the use of antiretrovirals, antifungals, antibiotics, antipyretics, 
immunosuppressive agents, corticosteroids, pump proton inhibitors, 
H2 receptor antagonists, sucralfates, analgesics, antidiabetic drugs, 
antihypertensive drugs, and others. Pump proton inhibitors, H2 
receptor antagonists, and sucralfates were the most commonly used 
drugs for comorbidities (25%), followed by antidiabetic drugs 
(14%), antihypertensive drugs (13%), and antibiotics (13%). 
 
Table 1: Patient characteristic based on research variables 
S. No. Variable  Frequency Percentage (%) 
1 Adverse reactions Minor adverse effects 127 73.8 
  Major adverse effects 45 26.2 
2 Treatment default No default 132 76.7 
  Default 40 23.3 
3 Age, y 15–54 134 77.9 
  >54 38 22.1 
4 Sex Female 67 39 
  Male 105 61 
5 Occupation Unemployed 72 41.9 
  Civil servant 8 4.7 
  Self-employed 34 19.8 
  Private sector worker 15 8.7 
  Other 43 25 
6 Anti-tuberculosis drugs Fixed-dose combination 118 68.6 
  Single-drug formulation 54 31.4 
7 Comorbid disease No 94 54.7 
  Yes 78 45.3 
8 Drug use for comorbid disease No 102 59.3 
  Yes 70 40.7 
 
 
Fig. 1: Distribution of major adverse effects of anti-tuberculosis drugs 
 
 
Fig. 2: Distribution of minor adverse effects of anti-tuberculosis drugs 
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Table 2: Association between adverse reactions to anti-tuberculosis drugs and treatment default cases 
Variable  No default (%) Default (%) OR (95% CI) P 
Adverse reactions Minor adverse effects 112 (88.2) 15 (11.8) 9.333 (4.204–20.721) <0.001 
 Major adverse effects 20 (44.4) 25 (55.6)   
OR, odds ratio; CI, confidence interval 
 
Table 3: Results of multivariate analysis for relationship of research variables with tuberculosis treatment default 
Variable  Constant  Standard error OR 95% CI P 
Adverse reaction 2.390 0.438 10.912 4.623–25.754 <0.001 
Anti-tuberculosis drugs 0.878 0.452 2.405 0.993–5.829 0.045 
Drug used for comorbid diseases 1.109 0.431 3.030 1.302–7.051 0.010 
Constant −2.881 0.439 0.56  <0.001 
OR, odds ratio; CI, confidence interval 
 
Adverse reactions to first-line anti-TB drugs as a risk factor of 
pulmonary TB treatment default 
We conducted bivariate analysis using the chi-square test. We found 
that several variables had an association with hypertension 
(p<0.05), namely, adverse reactions, formulation of anti-TB drugs, 
comorbid diseases, and drug use for comorbidities. Table 2 shows 
that major adverse reactions were associated with higher risk of 
treatment default (OR 9.33, 95% CI 4.204–20.721). In this study, 
multivariate analysis was performed using a logistic regression 
model including the following variables: adverse reactions, 
socioeconomic status, formulation of anti-TB drugs, comorbid 
diseases, and drug use for comorbidities. In the final model, those 
variables related to with treatment default were adverse reactions, 
formulation of anti-TB drugs, and drug use for comorbidities (table 
3). The final model variables associated with higher risk of 
treatment default were adverse reactions (OR, 10.91; 95% CI, 4.62–
25.75; p<0.001), drug use to treat concomitant diseases (OR, 3.03; 
95% CI, 1.30–7.05; p=0.01), and type of anti-TB drug used (OR, 2.41; 
95% CI, 0.99–5.83; p=0.045). 
DISCUSSION 
Demographically, we found that adverse reactions to anti-TB drugs 
were predominantly minor side effects (73.8%). This finding was in 
accordance with studies conducted by Nazir et al. (2015) and Lu et 
al. (2013) [5, 6]. The former authors showed that among a total 306 
patients in Lahore, Pakistan, only 31 patients (10.13%) experienced 
major adverse events (drug-induce hepatitis, shock, and 
hypersensitivity); the remaining 275 patients (89.87%) experienced 
minor adverse reactions, primarily muscle and joint pain [5]. Lu et 
al. conducted a study in China including 766 patients who 
experienced adverse reactions and found that 374 patients 
(48.83%) had major side effects, such as hepatic dysfunction and 
allergic reaction [6]. In our study, the predominant major adverse 
reaction was hepatotoxicity. Hepatotoxicity is affected by external 
and internal patient aspects. Hepatotoxicity occurs with excess 
accumulation of active metabolites of anti-TB drugs, causing failure 
of phase II metabolic detoxication, which is commonly regulated by 
transcription factors such as pregnane X receptor in the liver. 
Excessive metabolites could induce the production of reactive 
oxygen species (ROS), which cause further lipid peroxidation and 
cell death [7, 8]. The body has defensive mechanisms that are 
mediated by nuclear factor erythroid 2-related factor which has a 
cytoprotective profile [9]. Ramappa et al. (2013) explained that 
when this defensive aspect can protect against the harmful effects of 
oxidative stress caused by excessive metabolites or ROS, minimal 
side effects of anti-TB drugs occur. The main minor adverse 
reactions to these drugs involve gastrointestinal tract disorders, 
such as nausea [10, 11]. Kenward et al. (2015) showed that anti-TB 
drugs can cause nausea when active metabolite forms circulate, 
acting as emetogenic agents and stimulating vagal release of 5-
hydroxytryptamine [12]. 
The results of our final model showed that those variables related to 
treatment default were adverse reactions, formulation of anti-TB 
drugs, and drug usage for comorbidities. We found that major 
adverse reactions increased the risk of treatment default, in 
accordance with the findings of Rian (2010) and Muture et al. (2011) 
[13, 14]. The latter authors showed that anti-TB drug adverse 
reactions were the third leading factor in treatment default after 
lack of patient knowledge regarding TB treatment (16.7%) and long 
travel distance for patient treatment (12.5%). In addition, Muture et 
al. found that the incidence of adverse reactions was associated with 
patient inconvenience during therapy, which caused the patient to 
become noncompliant [13]. The formulation of anti-TB drugs is 
another factor contributing to the outcome of anti-TB therapy. In 
this study, we divided the formulation into fixed-dose combination 
and anti-TB drugs given in separate-dose form and found that the 
separate-dose form increased the risk for treatment default. In 
accordance with Gallardo et al. (2016), the use of fixed-dose 
combination has several advantages over the separate-drug form. 
The advantages of fixed-dose combination drugs are easier 
administration, convenient dose schedule and better compliance, and 
simplification of complex treatment regimens [15]. We also found that 
the use of other drugs for comorbidities have a role in TB treatment 
outcomes. Gastrointestinal medications (pump proton inhibitors, H2 
receptor antagonists, and sucralfates) were commonly used for 
comorbidities (25%). Omeprazole can interact with streptomycin and 
can disturb magnesium metabolism (hypomagnesemia) as well as 
parathyroid hormone secretion, which can contribute to 
hypocalcemia. Anti-diabetic drugs (such as metformin) can interact 
with isoniazid and lower glycemic control, causing hyperglycemia and 
glucose intolerance. Anti-hypertensive agents such as amlodipine can 
interact with rifampicin, which lowers the bioavailability, plasma 
concentration, and pharmacological effect of both drugs by induction 
of CYP450 3A4. The interaction between anti-TB drugs and 
medications taken for comorbidities also increases the risk of adverse 
effects and affects patient compliance [3, 4, 16]. 
CONCLUSION 
Based on our study results, we showed that adverse reactions to 
anti-TB drugs can affect treatment outcome and can serve as a risk 
factor of treatment default. We observed correlations of adverse 
reactions, anti-TB drug formulation, and drug use for comorbidities 
with treatment default in this study. We can conclude that 
problematic aspects of managing adverse drug reactions together 
with the management of comorbidities can lead to TB treatment 
default issues in patient populations worldwide. Public health 
authorities should focus on problems related to compliance among 
patients with TB, such as by developing programs to promote 
compliance and prevent default, within the context of traditional 
cultural values. 
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